Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs

Isabella Pötsch, Dina Baier, Bernhard Keppler, Walter Berger

Veröffentlichungen: Beitrag in BuchBeitrag in Buch/SammelbandPeer Reviewed

Abstract

Despite being “sentenced to death” for quite some time, anticancer platinum compounds are still the most frequently prescribed cancer therapies in the oncological routine and recent exciting news from late-stage clinical studies on combinations of metallodrugs with immunotherapies suggest that this situation will not change soon. It is perhaps surprising that relatively simple molecules like cisplatin, discovered over 50 years ago, are still widely used clinically, while none of the highly sophisticated metal compounds developed over the last decade, including complexes with targeting ligands and multifunctional (nano)formulations, have managed to obtain clinical approval. In this book chapter, we summarize the current status of ongoing clinical trials for anticancer metal compounds and discuss the reasons for previous failures, as well as new opportunities for the clinical translation of metal complexes.
OriginalspracheEnglisch
Titel Metal-based Anticancer Agents
Redakteure*innenAngela Casini, Anne Vessieres, Samuel M. Meier-Menches
Herausgeber (Verlag)Royal Society of Chemistry
KapitelCHAPTER 12
Seiten 308 - 347
Seitenumfang40
ISBN (elektronisch) 978-1-78801-767-1
ISBN (Print)978-1-78801-406-9
DOIs
PublikationsstatusVeröffentlicht - 23 Apr. 2019

Publikationsreihe

ReiheRSC Metallobiology
Nummer14
Band2019-January
ISSN2045-547X

ÖFOS 2012

  • 104003 Anorganische Chemie
  • 301904 Krebsforschung

Fingerprint

Untersuchen Sie die Forschungsthemen von „Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitationsweisen